Caffeine increases IOP and OPP in POAG

Article

Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients.

Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients. patients, claims a paper in Eye.

Dr A.Z. Jiwani et al., Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA, conducted a prospective, double-masked, crossover, randomized controlled trial on 106 subjects. Of these participants, 22 had high-tension POAG, 18 had normal tension, 21 POAG suspects and 25 healthy volunteers.

Each subject was given either 237 mL of caffeinated coffee or decaffeinated coffee at the first visit and the alternate beverage on the second visit. The outcome measures included blood pressure (BP) and pascal dynamic contour tonometer measurements of IOP ocular pulse amplitude (OPA) and heart rate. These were all measured before and at 60 and 90 minutes after coffee ingestion.

The results demonstrated no significant difference in baseline IOP, OPP and OPA between caffeinated and decaffeinated drinks. Mean mmHg changes in IOP, OPP and OPA were 0.99, 1.57 and 0.23, at 60 minutes, respectively. The results at 90 minutes for IOP, OPP and OPA were and 1.06, 1.26 and 0.18, respectively.

This suggests that consuming one cup of caffeinated coffee statistically increases but is not likely to clinically impact IOP and OPP in POAG cases.

The abstract can be found here .

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Colman Cawe, director of fundraising and communications, Orbis UK
Related Content
© 2023 MJH Life Sciences

All rights reserved.